Helix BioPharma 2023 Cancer Therapy Investor Presentation

Helix BioPharma is developing L-DOS47, a novel first-in-class tumor microenvironment modifying drug designed to break tumor defense against the immune system. The drug has demonstrated good tolerability and safety in over 100 patients with NSCLC and PDAC, showing promising results in combination with chemotherapy and checkpoint inhibitors. A 2023 funding round of $10M will support preclinical experiments toward partnership opportunities.